P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT

Bibliographic Details
Published in:HemaSphere
Main Authors: Anjali Cremer, Julius C. Enssle, Saskia Pfaff, Khouloud Kouidri, Fabian Lang, Christian Brandts, Andreas Zeiher, Sebastian Cremer, Björn Steffen, Hubert Serve, Gesine Bug
Format: Article
Language:English
Published: Wiley 2023-08-01
Online Access:http://journals.lww.com/10.1097/01.HS9.0000972164.39454.e5
Description
ISSN:2572-9241

Similar Items